肾细胞癌诊断性DNA甲基化生物标志物的系统评价
该系统评价检索截至2019年1月的文献,纳入19篇文章报告44个诊断性DNA甲基化生物标志物和11个多标志物组合,仅15个经独立验证。STARD评分4至13分(中位10分),无标志物超过证据等级III,报告不充分限制临床转化。
要点
- 早期肾细胞癌5年生存率约93%,转移后降至12%,早期检测至关重要。
- 纳入44个DNA甲基化标志物和11个多标志物组合,仅15个经独立验证。
- 无标志物超过证据等级III,报告不充分阻碍临床转化。
核心结论
- 所报告的DNA甲基化生物标志物均未超过证据等级III,临床效用有限。
- 研究可重复性和进一步开发受报告不充分严重制约。
研究设计与样本
- 系统评价检索PubMed、EMBASE、Medline和Google Scholar截至2019年1月,遵循PRISMA-DTA指南。
- 纳入19篇文章,报告44个诊断性DNA甲基化生物标志物和11个多标志物组合。
- 采用STARD标准评分,生成森林图汇总诊断性能,确定证据等级和偏倚风险。
主要发现
- 仅15个生物标志物经独立验证。
- STARD评分范围4至13分(总分23),中位10分。
- 亚组、方法和引物位置存在较大变异。
- 无生物标志物超过证据等级III,多数研究报告不充分。
关键数值与推荐
- 早期肾细胞癌5年生存率约93%,转移后5年生存率降至12%。
- STARD评分中位10分(范围4-13分,总分23分)。
- 证据等级均未超过III级。
临床怎么用
- 目前DNA甲基化生物标志物尚不能用于肾细胞癌临床诊断。
- 需改进报告规范以促进可重复性和进一步开发。
局限性
- 研究间亚组、方法和引物位置变异大。
- 多数研究报告不充分,影响可重复性。
- 仅15个标志物经独立验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The 5-yr survival of early-stage renal cell carcinoma (RCC) is approximately 93%, but once metastasised, the 5-yr survival plummets to 12%, indicating that early RCC detection is crucial to improvement in survival. DNA methylation biomarkers have been suggested to be of potential diagnostic value; however, their current state of clinical translation is unclear and a comprehensive overview is lacking. OBJECTIVE: To systematically review and summarise all literature regarding diagnostic DNA methylation biomarkers for RCC. EVIDENCE ACQUISITION: We performed a systematic literature review of PubMed, EMBASE, Medline, and Google Scholar up to January 2019, according to the Preferred Reporting Items for Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA) guidelines. Included studies were scored according to the Standards for Reporting of Diagnostic Accuracy Studies (STARD) criteria. Forest plots were generated to summarise diagnostic performance of all biomarkers. Level of evidence (LoE) and potential risk of bias were determined for all included studies. EVIDENCE SYNTHESIS: After selection, 19 articles reporting on 44 diagnostic DNA methylation biomarkers and 11 multimarker panels were included; however, only 15 biomarkers were independently validated. STARD scores varied from 4 to 13 out of 23 points, with a median of 10 points. Large variation in subgroups, methods, and primer locations was observed. None of the reported biomarkers exceeded LoE III, and the majority of studies reported inadequately. CONCLUSIONS: None of the reported biomarkers exceeded LoE III, indicating their limited clinical utility. Moreover, study reproducibility and further development of these RCC biomarkers are greatly hampered by inadequate reporting. PATIENT SUMMARY: In this report, we reviewed whether specific biomarkers could be used to diagnose the most common form of kidney cancer. We conclude that due to limited evidence and reporting inconsistencies, none of these biomarkers can be used in clinical practice, and further development towards clinical use is hindered.
引用
- Lommen K, Vaes N, Aarts MJ, et al. Diagnostic DNA Methylation Biomarkers for Renal Cell Carcinoma: A Systematic Review. Eur Urol Oncol. 2019. PMID: 31402218. doi:10.1016/j.euo.2019.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。